A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...
Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Pharmaceutical Technology on MSN14h
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJ&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Zacks Investment Research on MSN11h
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
More than 150,000 Americans could get diagnosed with colorectal cancer this year, but lifestyle changes can lower your risk, ...
In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Apr. 24, 2024 — Study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback